Selective Targeting of Cancer Stem Cells by 2-Aminodihydroquinoline Analogs

Heejoo Park1, Yeongji Yu, Hyejin Kim

  • 1Research Center for Cell Fate Control, College of Pharmacy, Sookmyung Women's University.

Insights

Two novel aminodihydroquinoline compounds show promise against cancer stem cells (CSCs). Compound 5i selectively eliminates CSCs in glioblastoma and colon cancer, offering a potential new strategy against chemotherapy resistance and recurrence.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Aminodihydroquinoline compounds are investigated for general cytotoxicity.
  • Cancer stem cells (CSCs) are implicated in chemotherapy resistance and tumor recurrence.
  • The anti-CSC activity of aminodihydroquinolines remains largely unexplored.

Purpose of the Study:

  • To evaluate the CSC-selective targeting activities of novel 2-aminodihydroquinoline analogs.
  • To investigate the mechanisms underlying their effects on CSCs and bulk cancer cells.

Main Methods:

  • Synthesis and testing of 10 2-aminodihydroquinoline analogs.
  • Assessment of cytotoxicity on glioblastoma and colon cancer cell lines (CSCs and bulk cultures).
  • Fluorescence-activated cell sorting (FACS) analysis and gene expression profiling.

Main Results:

  • Compound 5h exhibited general cytotoxicity and an initial increase in CSCs, followed by suppression.
  • Compound 5i demonstrated potent, selective elimination of CSCs with minimal impact on bulk cells.
  • Differential gene expression patterns were observed, suggesting distinct molecular pathways for 5h and 5i.
  • Selective anti-CSC effects were confirmed in both glioblastoma and colon cancer cell lines.

Conclusions:

  • Novel aminodihydroquinoline compounds 5h and 5i possess distinct anti-CSC activities.
  • Compound 5i shows significant potential for selective CSC targeting, independent of general cytotoxicity.
  • These compounds may offer new therapeutic avenues for overcoming chemotherapy resistance and preventing tumor recurrence in brain and colon cancers.

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K